News | July 30, 2025
Vijaya Diagnostic reports Q1 FY26 consolidated PAT at Rs. 38.33 Cr
The company would be commissioning 3 hubs in Q2 FY26 across our Core Geography and West Bengal
The company would be commissioning 3 hubs in Q2 FY26 across our Core Geography and West Bengal
The savings will be fully reinvested to support new product launches and its pipeline across multiple therapeutic areas
Aman holds a bachelor’s degree in economics from Boston University and an MBA from Columbia University, New York
The latest BioE3 policy builds the framework for high-performance biomanufacturing to propel the development and production
This achievement is part of the population-based initiative for screening, prevention, and management of Non-Communicable Diseases
This case report is jointly authored by US clinicians from leading hospitals, Houston Methodist Hospital, Weill Cornell Medical College and Johns Hopkins
GSK and Hengrui Pharma enter agreements to develop up to 12 innovative medicines across Respiratory, Immunology & Inflammation and Oncology
Carbamazepine Extended-Release Tablets are indicated for use as an anticonvulsant drug
The scheme aims to avoid disruption in supply of critical active pharmaceutical ingredients (APIs) used to make critical drugs
Both these products will be manufactured at Lupin’s Injectable facility at Nagpur, India
Subscribe To Our Newsletter & Stay Updated
